Next Article in Journal
Places to Smoke: Exploring Smoking-Related Practices among Danish Adolescents
Previous Article in Journal
Usefulness of Linear Mixed-Effects Models to Assess the Relationship between Objective and Subjective Internal Load in Team Sports
Article

Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study

1
Servicio de Farmacia, Complejo Hospitalario de Toledo, 45004 Toledo, Spain
2
Servicio de Farmacia, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
3
Servicio de Farmacia, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain
4
Servicio de Farmacia, Hospital Universitari Arnau de Vilanova, 25198 Lleida, Spain
5
Servicio de Farmacia, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, 15706 A Coruña, Spain
6
Servicio de Farmacia. Hospital Universitario Virgen de las Nieves, 18014 Granada, Spain
7
Servicio de Oncología Médica, Complejo Hospitalario de Toledo, 45007 Toledo, Spain
8
Pharmacoeconomics & Outcomes Research Iberia, 28224 Madrid, Spain
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(2), 394; https://doi.org/10.3390/ijerph18020394
Received: 30 November 2020 / Revised: 1 January 2021 / Accepted: 3 January 2021 / Published: 6 January 2021
(This article belongs to the Section Digital Health)
Background: Patients with lung cancer (LC) are at significantly higher risk of developing venous thromboembolism (VTE), which may lead to increased use of health resources and the cost of the disease management. The main aim of the study was to determine the cost of the management of VTE events in patients with LC treated with Low Molecular Weight Heparins (LMWH) in Spain. Methods: Costecat was an observational, ambispective pharmacoeconomic study. Patients with LC, with a first episode of VTE (symptomatic or incidental) in treatment with LMWH, were recruited from six third-level hospitals and followed up for six months. Sociodemographic, clinical and resource use variables of VTE-related implications and its treatment were collected. Direct healthcare costs and direct non-healthcare costs were recorded. Data collection was documented in an electronic case report. Costs (€2018) were estimated from the healthcare perspective. Statistical analysis was performed using the statistical program R 3.4.3 version (30 November 2017). Results: Forty-seven patients were included. Mean age was 65.4 years, 66.0% were male. The percentage of patients with LC who had metastatic disease was 78.7%. Twenty-three patients (48.9%) needed hospital admissions due to thromboembolic episode. Total average cost of patients with cancer associated VTE (CAT) was €10,969.6 per patient/semester. The hospitalizations represent 65.8% of total costs (7207.3 € SD 13,996.9 €), followed by LMWH therapy which represents 18.6% (2033.8 € SD:630.5 €). Conclusions: Venous thromboembolism episodes induce an economic impact on patients and healthcare systems. Direct healthcare costs are the major burden of the total cost, in which hospitalizations are the main drivers of cost. View Full-Text
Keywords: cancer; thromboembolic disease; LMWH; cost; economic impact cancer; thromboembolic disease; LMWH; cost; economic impact
MDPI and ACS Style

Rubio-Salvador, A.R.; Escudero-Vilaplana, V.; Marcos Rodríguez, J.A.; Mangues-Bafalluy, I.; Bernardez, B.; García Collado, C.; Collado-Borrell, R.; Alvarado Fernández, M.D.; Chacón López-Muñiz, J.I.; Yébenes Cortés, M.; Gómez Barrera, M.; Calleja-Hernández, M.Á. Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study. Int. J. Environ. Res. Public Health 2021, 18, 394. https://doi.org/10.3390/ijerph18020394

AMA Style

Rubio-Salvador AR, Escudero-Vilaplana V, Marcos Rodríguez JA, Mangues-Bafalluy I, Bernardez B, García Collado C, Collado-Borrell R, Alvarado Fernández MD, Chacón López-Muñiz JI, Yébenes Cortés M, Gómez Barrera M, Calleja-Hernández MÁ. Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study. International Journal of Environmental Research and Public Health. 2021; 18(2):394. https://doi.org/10.3390/ijerph18020394

Chicago/Turabian Style

Rubio-Salvador, Ana R., Vicente Escudero-Vilaplana, José A. Marcos Rodríguez, Irene Mangues-Bafalluy, Beatriz Bernardez, Carlos García Collado, Roberto Collado-Borrell, María D. Alvarado Fernández, José I. Chacón López-Muñiz, María Yébenes Cortés, Manuel Gómez Barrera, and Miguel Á. Calleja-Hernández. 2021. "Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study" International Journal of Environmental Research and Public Health 18, no. 2: 394. https://doi.org/10.3390/ijerph18020394

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop